Pedram Razavi

Oct 17, 2024 | nature.com | Nicholas Mai |Pedram Razavi |Anton Safonov |Chau Dang |Larry Norton |Mark E. Robson | +1 more

AbstractAfter disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.

Sep 18, 2023 | targetedonc.com | Komal Jhaveri |Pedram Razavi

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts DiscussIn season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Sep 11, 2023 | targetedonc.com | Komal Jhaveri |Pedram Razavi

BMI May Positively Impact the Pharmacodynamics of Palbociclib in Patients With eBCAccording to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

Aug 28, 2023 | targetedonc.com | Komal Jhaveri |Pedram Razavi

BMI May Positively Impact the Pharmacodynamics of Palbociclib in Patients With eBCAccording to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

Aug 28, 2023 | targetedonc.com | Komal Jhaveri |Pedram Razavi

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.